<SEC-DOCUMENT>0001193125-17-213390.txt : 20170626
<SEC-HEADER>0001193125-17-213390.hdr.sgml : 20170626
<ACCEPTANCE-DATETIME>20170626170102
ACCESSION NUMBER:		0001193125-17-213390
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20170626
DATE AS OF CHANGE:		20170626
EFFECTIVENESS DATE:		20170626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		17930440

	BUSINESS ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d414000ddefa14a.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Additional Materials</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a party other than the
Registrant&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Under Rule 14a-12</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA,
INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount previously paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g414000nnimx1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;26, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear
Stockholders, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have received a number of questions from our stockholders regarding the proposals set forth in our proxy statement (the &#147;Proxy
Statement&#148;) relating to the Galena Biopharma, Inc. Special Meeting of Stockholders to be held on July&nbsp;6, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have called the Special
Meeting to address challenges to actions approved at prior meetings of stockholders. For the reasons set forth in the Proxy Statement, our Board of Directors recommends that you<B> VOTE FOR</B> all the proposals set forth in the Proxy Statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>As explained in the Proxy Statement, voting against the proposals set forth in the Proxy Statement may, among other things, prevent us from completing
a strategic transaction and, consequently, could result in our filing for bankruptcy or an involuntary petition for bankruptcy being filed against us. <U>We believe this would be the worst possible outcome for stockholders</U>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In response to questions we have received from some of our stockholders, we note the following regarding the proposals set forth in the Proxy Statement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Proposals 1, 2, 3, and 4 relate to ratifying the filing and effectiveness of amendments to our certificate of incorporation that increased the number of shares of common stock we are authorized to issue. The vote
<B>FOR</B> these ratification proposals will: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>NOT </B>dilute your ownership in Galena; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>NOT </B>change the current total number of shares of our common stock that is outstanding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>NOT </B>change the current number of shares of common stock that we are currently authorized to issue; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>NOT </B>change the number of shares of common stock that you currently own. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
ratifications will merely confirm matters that were previously approved by our stockholders and are currently in effect. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Proposal 5 ratifies the previously approved reverse stock split that became effective on November&nbsp;11, 2016. <B>This is NOT a request for approval of a new reverse stock split</B>. A vote <B>FOR</B> this proposal
will not change the number of shares you own and is simply a confirmation of the previously approved reverse stock split. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is
very important.</B> If you are a stockholder whose shares are held at a brokerage firm, it is imperative that you instruct your broker to vote your shares as unvoted shares may prevent the approval of the proposals contained in the Proxy Statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors and stockholders of Galena are urged to read the Proxy Statement because it contains important information about the proposals discussed
above.</B> The Proxy Statement was filed with the SEC on June&nbsp;9, 2017 and mailed to stockholders on or about June&nbsp;12, 2017. The Proxy Statement can be found on the SEC Filings section of our website: www.galenabiopharma.com, at
www.sec.gov, or by contacting Mackenzie Partners, Inc., whose contact information is set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Please vote via the internet (www.proxyvote.com)
or telephone (toll-free number on the voting card sent to you). You will need to have your voting instruction form in hand. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2000 Crow
Canyon Place, Suite 380, San Ramon, CA 94583 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +1 (925) <FONT STYLE="white-space:nowrap">498-7700</FONT> &#9679; Fax: +1 (925) <FONT
STYLE="white-space:nowrap">498-7799</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: info@galenabiopharma.com &#9679; www.galenabiopharma.com </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for your cooperation, and we appreciate your support. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Stephen F. Ghiglieri </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen F. Ghiglieri </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Chief Executive Officer and Chief
Financial Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>If you have questions or need assistance in voting your shares, please contact:</I> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g414000img2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, New York 10016 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(212)
929-5500 (Call Collect) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">or </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Call Toll-Free (800) 322-2885 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: <U>proxy@mackenziepartners.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +1 (925) <FONT STYLE="white-space:nowrap">498-7700</FONT> &#9679; Fax: +1 (925) <FONT STYLE="white-space:nowrap">498-7799</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: info@galenabiopharma.com &#9679; www.galenabiopharma.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g414000img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g414000img2.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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MZY^%?QVTOP%^QEX0^(?Q4U:1X+7PS!/=W$SYDNY0@ 49^\[-P!ZF@#Z-$@)
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M=/N;CG/F7+H3,Q]]^:^N]"^)/B/]N+PI\.?@)\)Y[JQ\):/HEHWC[6PI48C
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M*[G8M@^F: .D_8 ^!GQ:^+_CCQ'X_P#A!XJTWPMJ6CNR3:MJ5L;@2S7 )95
M_B(SD^]?K5^S3\/_ (M>"=/U<_M >.[/QI>74L?]GBTL_(2VC4$-GU+$C\J^
M!_V*?VJ?^&9?A78^"1\$OB/J.KWM^\U_?PV9C21Y& 7[RYPH Z^]?JMHEX^H
MZ;;74]N]I+<0I(]N[!C$2,[21U(H OT444 4M6U.WT>PN;W4'$5M9P/--(?X
M44$M^@KXK_X)]P7'Q/\ &/Q:^..K*6?QEKSZ?I#M_P L[.W.T >QX/XUVO\
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MC^*/$&L^&Y[S2M4D-G;+>1DI=Z<F!$()<<$*!P#0!^K7P!^/^F_'6PUN73M
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g414000nnimx1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g414000nnimx1.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
MM1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#
M! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1
M Q$ /P#]_**** "BBB@ HHHH *H>*?%.F^"/#E]K&L7UKIFE:;"UQ=W=S*(X
M;>-1EG9CP !4/BOQSHW@72;R_P!:U73]*L].M9+ZZFNIUB2"",9>5B3PB]ST
M%?F-_P % _\ @K?KOQI_9DOO%?P"L_#OB;X?Z3?FQ\3ZA?6!N=7\/2I+^XN6
MLI04%M(0&CN"' .,JA&#Z67976QE10@K*Z3;T2OMKY]/,X,?F%/#4I3>K2>B
MW=O+\SZX^&/_  5-^'?CKP7K_B76;/Q)X'\.:=>-!I%_X@L3:CQ1" ,7%E'S
M)(A;(P5!X!]<>0>)_P#@K?J/QB^*VA>$_AGIL.E6VKZI!9#5=60-+*K2*I*Q
M#(0$''.X\] >GX]S?M):S\3_ !++K/B/6]0US5;K'FW=Y<--*P'0 D\ >@P!
MV KW3]F#XGQ>%O\ A,O&LDF+7P%X2U/5V+':K3-;M;6T>_K&SSSQJK $A]OK
MD?JM+@W+L%0GB:BYYV]U/6*=K+3[7O6WT_NH_#<UXQS[,<=0P&&?L:<IQ4G'
M2;C>\O>^SI?X=5_,S]\O!GB^P^('A'3-<TJ8W&FZO;1W=K*4*&2-U#*=I (R
M".",UIUY)^P/(TW[#WP?=V9W;P9I)9B<EC]CBR37K=?CM>"A4E!;)M'[]2DY
M04GNT%%%%9%A1110 4444 %%%% !1110 4444 5-?U5M"T.\O5M+S4&M(7F%
MM:J'GN-H)V("0"QQ@ D<GK7Y@^,O^"V/Q+_:W^-^I?"[X ^ -4\.7FE/+'K&
MK^(K%GU'2HHVV2S-9*&,03N")')( 3)&?U)KXL_;P_8/U&S_ &D?!W[1_P *
M;)[?QOX1F,/B[2],'DW?C#1G41SI&PX-U'$6*9&7PH!W+'7M9)7PM.J_K$%)
MV]UOX5+I==4_/1=3SLSPU:O2Y*4W'O;1M>3Z>J/R#_X**_M-?%?Q3XRU/P%J
M-I\2?#7A 21Q:G<>)[.>SU'QG.,2+<W>\#;#QNAM5.V-.6!<L:ROV)_BEX@_
M9L^(%OXB\.20OOB:TU"PN4\VRUBT?B6UN(SQ)$XXP>AP1@BOK']H']N[XQ_L
M[^/=:\*S>+)/$FD:=-(+2W\2Z?!J<5W;2@M#,PF5F):)U(^8X#D=,BO%-3_X
M*>?#Z]>"+QU^SMX#OGB,,3ZAX2NYO#UT(D^^?+3=$SL23T4<XZ8Q^RX6E.EA
M^6I152$EO%K5-;M24>G2[MLC\0Q&8RS-JCES>'J4W91FFK23U]Z+DV[WNVM7
MJS _;I_8ATS0/A[-\=/@C:W<WPSGE'_"2>'=QEO? %TW5&QR]DQ_U<O\((#5
ME?LC>#=9^-7[+?BS0=($<%Q\5/%&D>!_[2,@*:;91+-J>HRS*W2%(;:*0R#D
M>21D G/U-_P3S_; ^%/Q5^+5K8_"K2_C7IVN7]O<6NKZ-J/AF/Q+H=_:Y^:"
MZEMBN(VC./FC^5F7)]?>OV\OV$_#_P"SA^P[/X1^ D7@_P -W/Q$UB]$,FO^
M)H-/-I:Z@L,EW9:>TY 9I?LL,2H&W+&77.":^=S#./93C@8R;3:LY:.*3O[U
M]'9K1IOF6^JU^XR3+\35A]:S6@H5Z:>L6G&HK6YHI.Z?=-*SVT>GJO\ P2=_
MX*A_"O\ :9TAOA3X:BN_#MYX#C_LCP];ZC<>8_B'2[51%#=1O@?O#&@9XC\R
MYR,C)'V[7\X'A#]A;XS_ +-6NZ;JM_X'\7Z%=Z?<1O9ZG80FYCCG W*8KBW+
MH6&#]UC@@@]Q7["_\$X?^"CT/[1NC6WA+QK+!I_C^T38LA BBUH+U95_AF&/
MF3OR1QD#Y[B'A14Z;QV72]I3^U9W:\]-UW[>FVV4<=T)X[^S,P7LJDG:%U92
M_NZ[2[=_7?ZZHHHKX,_0@HHHH **** "BBB@ HHHH **** "BBB@#\XO^"VG
M[!-O\8_&?A[XA?\ "<^#/ &G"S?3=<O_ !%=FWA B#20-$J@M-*P+J4'S85<
M9QBO@72?!7[+7PDD86FG>(/CYXA +)?ZV9-$\/PN<;0+2,^?,%]7<!B/[IK]
MT?VN/ASI/Q5_9M\9:-K?A6S\:V,VES2_V-<2&(7KHA=52159HY,@;74$JV"*
M_F;^)UC#\'O%=FVE:NNN>%=>A-]HNH;#'*T6XJUO<1GF*ZA;Y)8R3@@,,JZD
M_K'!F,^N8?ZKB9RM3T26B:U>K7O7\KI676SM^7\6Y17PM2>,RR*4ZFK=KM/R
M3T5][V;OU1]M7'[6GBKXEV%OX:L)[#PQX<FG2.T\/^';1-,TV G:B#RX@"^
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MM?L-,E\NYO;2WDQG;+,J''T)JQ!<1W4*R1.DD;C*LIRK#U!IV>XDU>Q\W_\
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M/&6A_P#(#\6Z?;H]_IRELM ZG FMVR28V(P3N4J<D_6M]J=MIB*US<06ZL<
MRR! 3^-+9:E;ZG&7MIX;A%."T;AP#Z<4[.UQ75['E?P$_9OU/]F7]B7PM\*?
M"WB2*;6/!7A.#PYI6O7^GAD,\%L(8KJ2W5P" RJYC#\XQN[UY/\ \$B_^"6F
MG_\ !+SX+^)M+NO$\OC_ ,?>/M>G\0^*O%=Q9_99]8G=CL4H7<A4#,>6.7EE
M;C=@?5]Q<QVD)DED2*->K.P4#\31-<1VX4R.D89@H+$#)/0?6E8=SRC]N?\
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*MTHN3N[+\C__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
